Evidence map›Paper›PMID 28777929›Full record

ReviewAmerican journal of human genetics2017

Human Germline Genome Editing.

Kelly E Ormond, Douglas P Mortlock, Derek T Scholes, Yvonne Bombard, Lawrence C Brody, W Andrew Faucett, Nanibaa' A Garrison, Laura Hercher, Rosario Isasi, Anna Middleton and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of human genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Exploring gene editing as a potential therapeutic strategy for hemophilia.Frontiers in bioengineering and biotechnology · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Kelly E OrmondDepartment of Genetics and Stanford Center for Biomedical Ethics, School of Medicine, Stanford University, Stanford, CA 94305, USA. Electronic address: kormond@stanford.edu.
Douglas P MortlockVanderbilt Genetics Institute and Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN 37232, USA.
Derek T ScholesAmerican Society of Human Genetics, Bethesda, MD 20814, USA.
Yvonne BombardLi Ka Shing Knowledge Institute of St. Michael's Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON M5B 1W8, Canada.
Lawrence C BrodyDivision of Genomics and Society, National Human Genome Research Institute, Bethesda, MD 20892, USA.
W Andrew FaucettGenomic Medicine Institute, Geisinger Health System, Danville, PA 17822, USA; National Society of Genetic Counselors.
Nanibaa' A GarrisonTreuman Katz Center for Pediatric Bioethics, Seattle Children's Hospital and Research Institute, Seattle, WA 98101, USA; Division of Bioethics, Department of Pediatrics, University of Washington, Seattle, WA 98101, USA.
Laura HercherNational Society of Genetic Counselors; Joan H. Marks Graduate Program in Human Genetics, Sarah Lawrence College, Bronxville, NY 10708, USA.
Rosario IsasiDr. John T. Macdonald Foundation Department of Human Genetics and Institute for Bioethics and Health Policy, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Anna MiddletonSociety and Ethics Research Group, Connecting Science, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Association of Genetic Nurses and Counsellors.
Kiran MusunuruCardiovascular Institute, Departments of Medicine and Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Daniel ShrinerCenter for Research on Genomics and Global Health, National Human Genome Research Institute, Bethesda, MD 20892, USA; International Genetic Epidemiology Society.
Alice ViraniProvincial Health Service Authority of British Columbia and Department of Medical Genetics, University of British Columbia, BC V6H 3N1, Canada; Canadian Association of Genetic Counsellors.
Caroline E YoungAmerican Society of Human Genetics, Bethesda, MD 20814, USA.

Funding

Genetic epidemiology of complex diseasesZIAHG200362 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI ROTIMI, CHARLES · 2009 to 2025
$54.7M
The contribution folate and vitamin B12 genes to disease.ZIAHG000167 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BRODY, LAWRENCE C · 2009 to 2025
$17.6M
Genomics and Native Communities: Perspectives, Ethics, and EngagementK01HG008818 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GARRISON, NANIBAA' A · 2016 to 2020
$819k
Intramural NIH HHS ZIA HG200362NHGRI NIH HHS K01 HG008818
6 · The paper itself

Abstract

With CRISPR/Cas9 and other genome-editing technologies, successful somatic and germline genome editing are becoming feasible. To respond, an American Society of Human Genetics (ASHG) workgroup developed this position statement, which was approved by the ASHG Board in March 2017. The workgroup included representatives from the UK Association of Genetic Nurses and Counsellors, Canadian Association of Genetic Counsellors, International Genetic Epidemiology Society, and US National Society of Genetic Counselors. These groups, as well as the American Society for Reproductive Medicine, Asia Pacific Society of Human Genetics, British Society for Genetic Medicine, Human Genetics Society of Australasia, Professional Society of Genetic Counselors in Asia, and Southern African Society for Human Genetics, endorsed the final statement. The statement includes the following positions. (1) At this time, given the nature and number of unanswered scientific, ethical, and policy questions, it is inappropriate to perform germline gene editing that culminates in human pregnancy. (2) Currently, there is no reason to prohibit in vitro germline genome editing on human embryos and gametes, with appropriate oversight and consent from donors, to facilitate research on the possible future clinical applications of gene editing. There should be no prohibition on making public funds available to support this research. (3) Future clinical application of human germline genome editing should not proceed unless, at a minimum, there is (a) a compelling medical rationale, (b) an evidence base that supports its clinical use, (c) an ethical justification, and (d) a transparent public process to solicit and incorporate stakeholder input.

Indexed as

Gene EditingClustered Regularly Interspaced Short Palindromic RepeatsGenome, HumanHumansSocial ChangeCRISPRethicseugenicsgene editinggene therapygenetics policygenome editinggermlinehuman genomesociety

Identifiers

PMID28777929
PMCPMC5544380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.